CompletedNCT02032043

Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)

Studying Filariasis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Washington University School of Medicine
Principal Investigator: Gary J Weil, MD
Washington University School of Medicine
Intervention: Annual versus Semiannual Albendazole plus Ivermectin MDA(drug)
Enrollment: 14457 enrolled
Eligibility: 5 years · All sexes
Timeline: 2014 – 2017

Study locations (1)

Ivory Coast National Program Against Schistosomiasis, Geohelminths and Filariasis, Abidjan, Lagune-Cocody, Côte d’Ivoire

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02032043 on ClinicalTrials.gov

Other trials for Filariasis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001230
Host Response to Infection and Treatment in Filarial Diseases
National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for Filariasis →

← Back to all trials